Matinas biopharma announces that mat2203 will be featured in two oral presentations at eccmid

Bedminster, n.j., march 02, 2023 (globe newswire) -- matinas biopharma (nyse american: mtnb), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (lnc) platform delivery technology to maximize global clinical impact and patient access, announces that mat2203, an oral lnc formulation of amphotericin b (amb), will be featured in two oral presentations at the 33 rd european congress of clinical microbiology & infectious diseases (eccmid). the hybrid in-person and virtual congress is being held april 15-18 in copenhagen and the mat2203 presentations will both take place on april 18.
MTNB Ratings Summary
MTNB Quant Ranking